The U.S. Food and Drug Administration today announced a pilot program designed to streamline communications with sponsors following formal meetings.
Similar Posts
Advisory Letters
Advisory LettersFDA’s ISTAND Pilot Program accepts submission of first artificial intelligence-based and digital health technology for neuroscience
FDA’s Center for Drug Evaluation and Research (CDER) recently accepted a new submission into the Innovative Science and Technology Approaches for New Drugs (ISTAND) Pilot Program. This submission is the first artificial intelligence-based and digital health technology-based project and the first proCenter for Biologics Evaluation and Research & Center for Drug Evaluation and Research Real-World Evidence
As defined by FDA, real-world data (RWD) are the data relating to patient health status and/or the delivery of health care routinely collected from a variety of sources and real-world evidence (RWE) is the clinical evidence regarding a medical product’s use and potential benefits or risks derived frGDUFA IV: Fiscal Years 2028 – 2032
Information related to FDA’s preparation for the fourth reauthorization of GDUFA will be hosted on this page as it becomes available.National Drug Code Database Background Information
National Drug Code Database Background InformationCaraco Pharmaceutical Laboratories. Recall Enterprise System (RES)Digoxin Recall Details
Caraco Pharmaceutical Laboratories. Recall Enterprise System (RES) recall details